NASDAQ:OMER - Omeros Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $18.62 -0.02 (-0.11 %) (As of 05/21/2019 01:05 AM ET)Previous Close$18.64Today's Range$18.22 - $18.6652-Week Range$10.30 - $27.00Volume383,498 shsAverage Volume585,733 shsMarket Capitalization$913.46 millionP/E RatioN/ADividend YieldN/ABeta3.57 ProfileAnalyst RatingsChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Omeros Corporation, a biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting inflammation, complement-mediated diseases, disorders of the central nervous system (CNS), and immune-related diseases. It provides OMIDRIA for use in cataract surgery or intraocular lens replacement in the United States. The company's clinical programs include Narsoplimab (OMS721/MASP-2) that is in Phase III clinical trial for hematopoietic stem-cell transplant-associated thrombotic microangiopath, immunoglobulin A nephropathy, and atypical hemolytic uremic syndrome; and Phase II clinical trial to treat lupus nephritis and other renal diseases. Its clinical programs also consists of PDE10 (OMS824) which is in Phase II clinical trial for treating Huntington's disease and schizophrenia; PPAR? (OMS405) that is in Phase II clinical trial to treat opioid and nicotine addiction; and PDE7 (OMS527), which is in Phase I clinical trial for treating addiction and compulsive disorders, and movement disorders. In addition, the company's preclinical programs comprise MASP-3 (OMS906) for paroxysmal nocturnal hemoglobinuria (PNH) and other alternative pathway disorders; MASP-2-small-molecule inhibitors used for the treatment of aHUS, IgAN, HSCT-TMA, and age-related macular degeneration; and MASP-3-small-molecule inhibitors to treat PNH and other alternative pathway disorders. Further, its preclinical programs include G protein-coupled receptor (GPCR) platform, including GPR174, GPR151, GPR161, and other Class A orphan GPCRs for treating immunologic, immuno-oncologic, metabolic, CNS, cardiovascular (CV), musculoskeletal, and other disorders; and antibody platform for metabolic, CV, oncologic, musculoskeletal, and other disorders. The company was incorporated in 1994 and is based in Seattle, Washington. Receive OMER News and Ratings via Email Sign-up to receive the latest news and ratings for OMER and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryPharmaceuticals SectorMedical Current SymbolNASDAQ:OMER Previous Symbol CUSIP68214310 CIK1285819 Webwww.omeros.com Phone206-676-5000Debt Debt-to-Equity RatioN/A Current Ratio1.73 Quick Ratio1.71Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$29.87 million Price / Sales30.58 Cash FlowN/A Price / Cash FlowN/A Book Value($2.47) per share Price / Book-7.54Profitability EPS (Most Recent Fiscal Year)($2.22) Net Income$-126,760,000.00 Net Margins-241.81% Return on EquityN/A Return on Assets-106.08%Miscellaneous Employees236 Outstanding Shares49,058,000Market Cap$913.46 million Next Earnings Date8/8/2019 (Estimated) OptionableOptionable Omeros (NASDAQ:OMER) Frequently Asked Questions What is Omeros' stock symbol? Omeros trades on the NASDAQ under the ticker symbol "OMER." How were Omeros' earnings last quarter? Omeros Co. (NASDAQ:OMER) posted its earnings results on Thursday, May, 9th. The biopharmaceutical company reported ($0.38) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.34) by $0.04. The biopharmaceutical company had revenue of $21.80 million for the quarter, compared to analyst estimates of $23.18 million. The company's revenue was up 1271.1% compared to the same quarter last year. During the same quarter in the previous year, the firm earned ($0.62) EPS. View Omeros' Earnings History. When is Omeros' next earnings date? Omeros is scheduled to release their next quarterly earnings announcement on Thursday, August 8th 2019. View Earnings Estimates for Omeros. What price target have analysts set for OMER? 5 analysts have issued 12-month target prices for Omeros' stock. Their predictions range from $18.00 to $35.00. On average, they expect Omeros' share price to reach $28.20 in the next twelve months. This suggests a possible upside of 51.5% from the stock's current price. View Analyst Price Targets for Omeros. What is the consensus analysts' recommendation for Omeros? 5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Omeros in the last year. There are currently 1 hold rating and 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Omeros. What are Wall Street analysts saying about Omeros stock? Here are some recent quotes from research analysts about Omeros stock: 1. According to Zacks Investment Research, "Omeros Corporation is a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing products focused on inflammation and disorders of the central nervous system. Omeros' most clinically advanced product candidates are derived from its proprietary PharmacoSurgery(TM) platform designed to improve clinical outcomes of patients undergoing arthroscopic, ophthalmological, urological and other surgical and medical procedures. Omeros has four ongoing PharmacoSurgery(TM) clinical development programs, and its lead product candidate, OMS103HP, is being evaluated in Phase 3 clinical trials for use during arthroscopic surgery to improve postoperative joint function and reduce postoperative pain. Omeros is also building a diverse pipeline of preclinical programs targeting inflammation and central nervous system disorders. " (5/10/2019) 2. HC Wainwright analysts commented, "We note that the performance vs. consensus was substantially more impressive, as Omeros delivered top-line results that were $6M ahead of consensus estimates and bottom-line numbers that were $0.26 better than consensus. Management indicated on its earnings conference call the strong year-end performance of OMIDRIA, which is currently covered for nearly 90% of relevant lives and which is on a $100M annualized revenue run rate as of December 2018. Investors should note that we expect OMIDRIA revenue to meaningfully accelerate over the course of this year and well into 2020, with our full-year 2019 revenue projection currently at $165.4M and 2020 top-line revenue estimated at $242.3M. Given the strength of the OMIDRIA franchise and the potential for multiple near-term pipeline catalysts, notably the start of a possible regulatory filing in the U.S." (3/4/2019) 3. Maxim Group analysts commented, "Omeros reported 3Q18 with $4.6M in Omidria revenues, up from $1.7M in 2Q18. Omeros reported a net loss for the quarter of ($39.5M), and a cash balance of $55M, excluding the $210M debt offering announced concurrently. OMER shares are down ~20%, in our view, due to a misunderstanding of the financing." (11/9/2018) Has Omeros been receiving favorable news coverage? News stories about OMER stock have been trending somewhat negative recently, InfoTrie Sentiment reports. The research group identifies positive and negative press coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. Omeros earned a daily sentiment score of -1.6 on InfoTrie's scale. They also gave headlines about the biopharmaceutical company a news buzz of 10.0 out of 10, meaning that recent press coverage is extremely likely to have an effect on the company's share price in the next several days. Who are some of Omeros' key competitors? Some companies that are related to Omeros include HUTCHISON CHINA/S (HCM), Ultragenyx Pharmaceutical (RARE), ACADIA Pharmaceuticals (ACAD), Global Blood Therapeutics (GBT), FibroGen (FGEN), Agios Pharmaceuticals (AGIO), Amicus Therapeutics (FOLD), Reata Pharmaceuticals (RETA), Biohaven Pharmaceutical (BHVN), Arena Pharmaceuticals (ARNA), Mirati Therapeutics (MRTX), Amneal Pharmaceuticals (AMRX), Intercept Pharmaceuticals (ICPT), The Medicines (MDCO) and Myokardia (MYOK). What other stocks do shareholders of Omeros own? Based on aggregate information from My MarketBeat watchlists, some companies that other Omeros investors own include ACADIA Pharmaceuticals (ACAD), Array Biopharma (ARRY), Exelixis (EXEL), Inovio Pharmaceuticals (INO), Synergy Pharmaceuticals (SGYP), Verastem (VSTM), Ocular Therapeutix (OCUL), Flexion Therapeutics (FLXN), Portola Pharmaceuticals (PTLA) and Progenics Pharmaceuticals (PGNX). Who are Omeros' key executives? Omeros' management team includes the folowing people: Dr. Gregory A. Demopulos, Co-Founder, Chairman, CEO & Pres (Age 60)Mr. Michael A. Jacobsen, Chief Accounting Officer, VP of Fin. & Treasurer (Age 61)Ms. Marcia S. Kelbon, VP of Patent, Gen. Counsel & Sec. (Age 59)Dr. Pamela Pierce Palmer, Co-Founder (Age 56)Dr. George A. Gaitanaris, Chief Scientific Officer & VP of Science (Age 62) Who are Omeros' major shareholders? Omeros' stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include Ingalls & Snyder LLC (10.36%), BlackRock Inc. (7.79%), Cpwm LLC (1.47%), Northern Trust Corp (1.29%), Geode Capital Management LLC (1.16%) and Charles Schwab Investment Management Inc. (0.54%). Company insiders that own Omeros stock include Marcia S Kelbon and Michael A Jacobsen. View Institutional Ownership Trends for Omeros. Which major investors are selling Omeros stock? OMER stock was sold by a variety of institutional investors in the last quarter, including BlackRock Inc., Ingalls & Snyder LLC, Morgan Stanley, Parametric Portfolio Associates LLC, Cpwm LLC, National Asset Management Inc., California Public Employees Retirement System and California State Teachers Retirement System. View Insider Buying and Selling for Omeros. Which major investors are buying Omeros stock? OMER stock was purchased by a variety of institutional investors in the last quarter, including SG Americas Securities LLC, Geode Capital Management LLC, Tibra Equities Europe Ltd, State of Wisconsin Investment Board, Rhumbline Advisers, Charles Schwab Investment Management Inc., Northern Trust Corp and BNP Paribas Arbitrage SA. View Insider Buying and Selling for Omeros. How do I buy shares of Omeros? Shares of OMER can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Omeros' stock price today? One share of OMER stock can currently be purchased for approximately $18.62. How big of a company is Omeros? Omeros has a market capitalization of $913.46 million and generates $29.87 million in revenue each year. The biopharmaceutical company earns $-126,760,000.00 in net income (profit) each year or ($2.22) on an earnings per share basis. Omeros employs 236 workers across the globe. What is Omeros' official website? The official website for Omeros is http://www.omeros.com. How can I contact Omeros? Omeros' mailing address is 201 ELLIOT AVENUE WEST, SEATTLE WA, 98119. The biopharmaceutical company can be reached via phone at 206-676-5000. MarketBeat Community Rating for Omeros (NASDAQ OMER)Community Ranking: 3.1 out of 5 ( )Outperform Votes: 589 (Vote Outperform)Underperform Votes: 358 (Vote Underperform)Total Votes: 947MarketBeat's community ratings are surveys of what our community members think about Omeros and other stocks. Vote "Outperform" if you believe OMER will outperform the S&P 500 over the long term. Vote "Underperform" if you believe OMER will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 5/21/2019 by MarketBeat.com StaffFeatured Article: Derivative Receive Analysts' Upgrades and Downgrades Daily Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.